Cartesian Therapeutics Announces Additional Retreatment Data for Descartes-08 Highlighting Deep and Durable Responses in Patients with Myasthenia Gravis
Cartesian Therapeutics Inc RNAC
$7.24
▲ +0.42%
(+$0.03)
Open
$7.28
Prev Close
$7.21
Day Range
$7.10 – $7.56
52W Range
$5.60 – $11.00
Market Cap
$219.05M
Beta
0.75
EPS (TTM)
$-5.87
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2016-06-22 |
| Shares Out. | 29,380,000 |
| Website | cartesiantherapeutics.com/ ↗ |
| Phone | 13013488698 |
| Employees | 75 |
| Revenue | $0 |
| Gross Profit | $0 |
| Net Income | $15.8M |
| Free Cash Flow | -$78.6M |
| Total Assets | $318.6M |
| Total Liabilities | $443.9M |
| Equity | -$125.2M |
About Cartesian Therapeutics Inc
Cartesian Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering cell therapy for the treatment of autoimmune diseases. The company uses technology and a manufacturing platform to introduce mRNA into cells to provide a therapeutic effect to patients suffering from a variety of autoimmune conditions. Unlike DNA, mRNA degrades naturally over time without integrating into the cell's genetic material.
Cartesian Therapeutics Inc is a publicly traded company under the ticker symbol RNAC on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
14 analysts (2026-09-01)